SIRT6 and pulmonary fibrosis: The attractiveness of Sirt6 as a therapeutic target had been reported in the conditions of cardiac fibrosis, renal fibrosis, and idiopathic pulmonary fibrosis (Cai et al. 2022; Zhang et al. 2019).